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Abstract Introduction: Given mounting calls to disclose biomarker test results to research participants, we
explored factors underlying decisions by patients with mild cognitive impairment to receive amyloid
imaging results.
Methods: Prospective, qualitative interviews were conducted with 59 participants (305mild cogni-
tive impairment patients, 29 5 care partners) from the scan arm of a randomized controlled trial on
the effects of amyloid PET results disclosure in an Alzheimer Disease Research Center setting.
Results: Sixty-three percent of the participantswere female,with an average age of 72.9 years, andmost
had greater than a high school level of education (80%). Primary motivations included: (1) better under-
standing one’s mild cognitive impairment etiology and prognosis to plan ahead, and (2) learning one’s
brain amyloid status for knowledge’s sake, regardless ofwhether the information is actionable.Most par-
ticipants demonstrated an adequate understanding of the scan’s limitations, yet instances of character-
izing amyloid PET as a definitive test for Alzheimer’s disease occurred. Mention of potential
drawbacks, such as negative psychological outcomes, was minimal, even among care partners.
Discussion: Findings demonstrate a risk of disproportionate focus on possible benefits of testing
among amyloid scan candidates and suggest a need to clearly emphasize the limitations of amyloid
PETwhen counseling cognitively impaired patients and their families before testing. Future research
should examine whether minimizing drawbacks at the pre-imaging stage has adverse consequences
on results disclosure.
 2018 The Authors. Published by Elsevier Inc. on behalf of the Alzheimer’s Association. This is an
open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/).
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1. Introduction
Despite the rapid proliferation of imaging-based and
other biomarkers for Alzheimer’s disease (AD) in research
and practice, investigations into how patients and families
view undergoing predictive or diagnostic testing for AD
are limited. Understanding the motivations for, and
perceived drawbacks of, pursuing such testing will be crit-
ical to developing best practices for providing information
and support to candidates for AD biomarker testing. The
need for such data is underscored, on the one hand, by ad-
vocates for early detection of AD who are working to mini-
mize barriers to diagnostic testing [1], and on the other
hand, by commentators who caution against indiscrimin-
ately screening for AD pathology in the absence of a
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preventative or curative intervention for those who test pos-
itive [2,3].
Regarding positron emission tomography (PET) amyloid
imaging, there is growing consensus that patients and
research participants who will receive their scan results
should be adequately counseled before imaging [4–7].
Efforts to develop such pretest counseling (PTC) protocols
have focused on considerations unique to cognitively
healthy individuals [8] and those with mild cognitive impair-
ment (MCI) [7]. Early evaluations of protocols to inform
MCI patients of the benefits, risks, and limitations of amy-
loid PET have shown PTC to be well received and compre-
hensible to patients [7]. Yet, prospective studies of factors
influencing real-time decisions to pursue amyloid imaging
are limited. One recent study documented that the ability
to better understand one’s brain heath and make future deci-
sions to be the main reasons MCI research participants seek
amyloid PET results [9]. Extending this line of inquiry, we
examined factors influencing decisions to pursue amyloid
PET among both scan candidates with MCI and their family
members, focusing on a critical 2-week window following
PTC, but before scheduling a scan.
2. Methods
2.1. Study design, sample, and setting
We conducted a prospective, interview-based qualitative
study as part of a larger, ongoing investigation of how amy-
loid PET disclosure impacts the understanding of and ability
to cope with a diagnosis of MCI. Patients with MCI and their
care partners (typically family members) were recruited into
the ongoing parent study from the University of Pittsburgh
Alzheimer Disease Research Center (ADRC; NIA grant
P50 AG005133) beginning in October of 2015. Of the 113
ADRC participants invited by the ADRC staff, 75 (66%)
agreed to be referred to the parent study; to date, 72 of those
have enrolled. Primary reasons for declining to participate in
the parent study included health problems on the part of
either the patient or the care partner and concerns that the
study was very time consuming. Inclusion criteria for the
parent study were as follows: (1) a current ADRC consensus
diagnosis of MCI (isolated impairment in memory, isolated
deficit in non-memory domain, or mild deficits in multiple
cognitive domains) [10]; (2) the capacity to provide
informed consent as verified by the University of San Diego
Brief Assessment of Capacity to Consent [11,12]; (3)
residence within 100 miles from the university (to
facilitate home study visits); and (4) having a care partner
who also consented to participate. Exclusion criteria were
as follows: (1) familial AD genetic mutation carriers (this
group already has biomarker-based AD risk information);
and (2) active, untreated mood, or anxiety disorders defined
as a Hamilton Depression Rating Scale [13] score of.17 or
a Spielberger State Anxiety [14] score of.40. Care partner
participants had to be 18 years of age or older. The sample
for the sub study reported herein consists of the first 30 dyads
(participant 1 care partner) to undergo a qualitative inter-
view as described below.
2.2. Procedures
This research was approved by the University of Pitts-
burgh Institutional Review Board. All patients with MCI
and their care partners provided informed consent, but one
care partner later declined the qualitative interview. Baseline
interviews for the parent study included a 10-point self-
rating of interest in pursuing amyloid PET and receiving
the scan results. Higher ratings indicated greater interest in
obtaining a scan. Participants completed this scale at base-
line and following the qualitative interview that is the focus
of this report. After baseline data collection, all parent study
participants were randomized to a scan group with results
disclosure or to a comparison group with an MCI education
session. All participants were informed of their group
assignment at the completion of the baseline visit. An excep-
tion was made for individuals who had previously undergone
a research PETamyloid scan under a protocol that precluded
results disclosure. The randomization process was over-
ridden in these cases, and these individuals were placed in
the scan group, with the opportunity to undergo a new amy-
loid PET scan and results disclosure.
Scan group participants underwent formal PTC. Based on
a protocol described previously, PTC sessions were conduct-
ed by master’s prepared clinicians and included an overview
ofMCI and AD, followed by a presentation of the purpose of
amyloid imaging and its potential pros, cons, and limitations
in the context of MCI [7]. At the end of PTC, dyads were
encouraged to carefully consider whether or not they wanted
to pursue amyloid imaging. During a 2-week interim be-
tween PTC and the scheduling of the scan (if decided
upon), a qualitative interview was conducted to capture par-
ticipants’ perspectives on the decision-making process in real
time. The interview guide contained five semi-structured
questions (e.g., “Tellme about your experiencewith deciding
whether or not to get the scan.”) and 15 follow-up probes
(e.g., “What kinds of factors did you consider when making
your decision?”). Questions were open-ended and neutrally
worded (See Table 1). Interviewers were trained in qualita-
tive data collection and instructed to probe for clarification
when ambiguous or conflicting statements were made. Inter-
views were completed in participants’ homes by two study
staff members, one who interviewed the patient and another
who simultaneously interviewed the care partner. Interviews
were audio-recorded and transcribed verbatim.
2.3. Data analysis
The current report describes findings from qualitative anal-
ysis of the first 30 dyads in the scan group to undergo a quali-
tative interview after PTC. Descriptive analysis of this
subsamplewas conducted using IBM SPSS Statistics forWin-
dows, version 24.0. Interview data weremanaged inATLAS.ti
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7.0 andanalyzedusing thequalitativemethod of constant com-
parison [15]. This method centers the analysis on comparing
and contrasting data between and within interview transcripts
to determinewhether incidents fit or do not fit within emerging
categories and the properties that define them. Although each
member of the dyad was interviewed separately to ensure
adequate opportunity for the expression of individual thoughts
and feelings, their data were analyzed together to form a com-
plete representation of factors influencing the decision to be
scanned. Line-by-line coding of transcripts was performed
by three coders, categories were generated to label codes as
similarities emerged, and themes were developed as a result
of the constant comparison analysis.
3. Results
3.1. Sample characteristics
As Table 2 indicates, 63% of patient participants were fe-
male and 87% Caucasian, with an average age of 73 years.
Care partners were also primarily female (83%) and Cauca-
sian (86%), but slightly younger, with an average age of
68 years. Both patients and care partners reported relatively
high levels of educational attainment, with 80% of the total
sample having more than a high school level of education.
Most participants had expressed a high level of interest in
undergoing amyloid imaging on enrollment into the parent
study (Table 2). At the time of the qualitative interview, 24
of the 30 patients with MCI had made a decision to proceed
with the scan; the remaining individuals were either still
deciding (n5 4) or had decided against it (n5 2). Analysis
of the decision-making interviews revealed rich information
concerning participants’ motivations for, and perceived
drawbacks of, pursuing amyloid imaging. Key features of
the decision-making dynamic within this highly motivated
group were also identified.
3.2. Motivations
Patient (n 5 27) and care partner participants (n 5 21)
consistently cited the potential for the amyloid PET scan
to give them more information about the underlying cause
or likely course of their MCI as a major motivation for pur-
suing the scan. This motivation was often described in
conjunction with talk of plans to use the information for
planning ahead (see Table 3). While most participants
demonstrated an adequate understanding of the scan’s limi-
tations on probing, three patients and two care partners made
statements that equated amyloid positivity with an AD diag-
nosis. For example, one patient with MCI stated, “people.
want to know whether they have Alzheimer’s or not, which is
determined by the scan,” while another said, “I want to know
the defining thing on Alzheimer’s.so far [that] is that PET
scan and that’s testing amyloid, right?” In one additional
case, a care partner described her husband with MCI as
potentially equating a positive scan with an AD diagnosis,
“My only concern is that he’s going to, uh—if he, if he would
get a result that there was, you know, some plaque, some um,
that he is going to be—look at it more as a definitive diag-
nosis, even though you guys have said all along this is not
a diagnosis, it’s not, you know.”
There were also nine cases in which the potential to gain
information was characterized as a desire to know one’s
brain amyloid status for knowledge’s sake. The following
quote exemplifies this sentiment: “I want to know. [Even
though] You might not be able to do anything about it.” In
such cases, the emphasis was on the “right” to know the
Table 1
Semi-structured interview guide with probes
Introduction
The purpose of this interview is to learn about your experiences with deciding whether or not to undergo [or have your familymember undergo] a special type of
brain scan (amyloid scan) with the option of getting the results of that scan afterward. It is important that you express yourself openly. There are no right or
wrong answers. We want to know what you think.
1. Tell me about your (or your family member’s) decision to participate in an amyloid brain scan research study in the first place.
Probes:Why did you (or is your family member) participate in the research study?What motivated you (or your family member) to volunteer for a brain
scan study?
2. What were your first thoughts when you were asked if you wanted to be in a study where you could receive your (or your family member’s) research scan
results?
3. Tell me about your experience with deciding whether or not to get the scan and receive its results.
Probes: What kinds of factors did you consider when making your decision? Did you feel like you had all of the information that you needed in making
your decision? If not, what other information would have been helpful?
Who, if anyone, did you discuss your decision with? What was that discussion like?
How was your decision influenced by the fact that the scan was part of a research study, as opposed to something that your regular physician ordered?
How do you think the process of making this decision was different from other medical decisions you’ve made in the past?
4. At this point, have you (or has your family member) made a final decision or are you still thinking about whether or not to do the next scan and receive
your results?
If a decision has been made: How do you feel about your decision? What, if anything, if your biggest concern about your decision at this point in time?
Would you say that the information session influenced this decision? If so, how?
Were you leaning one way or another when you enrolled in the study?
5. How would you describe the type and amount of support that you have received during the decision-making process?
NOTE. Interview conducted within 2 weeks of formal pretest counseling session for amyloid imaging.
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results of one’s scan rather than the potential for the informa-
tion to clarify one’s diagnosis or explain one’s symptoms.
Even though it was not described as a primary motivator,
the research context emerged as a supporting factor that influ-
enced some in deciding to pursue an amyloid PET scan.
Research-related motivation took four distinct forms: (1) the
scan being free of charge, (2) scheduling and logistics being
handled by study staff, (3) the fact that as a research scan,
the results would not become part of the medical record, and
(4) a belief that participation in the scan process would
“help the researchers.”
3.3. Potential drawbacks
Overall, drawbacks of amyloid PETwere mentioned less
often than potential benefits. Indeed, some interviewees
stated that they perceived no risks associated with the
scan. This is exemplified by the statement, “I don’t see any
reason not to do it.” made by a 78-year-old woman with
MCI. In the few instances where drawbacks were mentioned,
such statements revealed a view that scan results would not
likely change one’s course of treatment. One patient ex-
plained that suicide may be a “rational” choice on receiving
a positive scan result, but in only two cases was there an
acknowledgment of the potential for a negative psychologi-
cal reaction to learning one’s brain amyloid status. For
example, one care partner stated that a positive scan result
“would affect him [her husband] badly.he’ll say, ‘I’m
going to wind up like..a vegetable.’” One patient who
decided against the scan stated, “I thought about knowing
that if it [the result] was bad, I’d be depressed.” and made
similar statements throughout the interview.
3.4. Features of the decision-making process
3.4.1. Deliberative speed
When asked to describe the decision-making process, 14
of the 30 dyads characterized the decision as being easy,
rapid, or requiring little deliberation, whereas only 4
described any prolonged consideration of whether to pro-
ceed with the scan. For example, one patient stated “I’m
on a. fence right now and 75% of me.is saying no to
the PET scan and the other 25% of me is saying ‘why
don’t you go ahead?’” while a care partner described second
thoughts stating, “The only thing I’m thinking of is, you
know, we said right off the bat, ‘Oh yeah, we want to
know.’ But I don’t know if it’s a good idea if both of us know.”
3.4.2. Feelings about the decision to be scanned or not
When asked how they felt about the decision, many par-
ticipants responded with descriptions about their feelings
regarding the prospect of learning their amyloid status,
rather than their feelings about the decision itself. Several
participants expressed positive feelings including “happy,”
“enthusiastic,” “good,” and “positive.” Others (n 5 6)
described neutral emotions (for example, stating they had
“no qualms”), but many (n5 18) used some form of negative
phrasing when describing their feelings. Negative feelings
often included anxiety, which was sometimes reported as be-
ing present despite an overall positive perspective on having
the scan. For example, one patient who voiced a “definite”
plan to proceed with her scan stated, “I would be.um.
remiss to say I’m not worried about it.”
3.4.3. Consultation with others
Responses to the question, “Who have you discussed the
possibility of getting this scan with?” frequently (n5 22 pa-
tients; n5 19 care partners) revealed little to no consultation
with individuals outside of the dyad other than the research
team. In only four instances was consultation with another
health-care provider or family member described.
Care partners typically described their role as supportive
in nature, emphasizing that the final decision rested with
the patient. Statements such as, “it’s her decision,” and
“You know, I might give my opinion, but.it’s him so he
needs to decide what he wants,” typified this sentiment.
This stance was present in a range of scenarios, from those
who admitted to disagreeing with the patient’s decision








Mean age in years (SD) 72.9 (8.94) 68.2 (9.67)
Education, n (%)
,H.S. 0 (0) 1 (3)
H.S./GED 6 (20) 5 (17)
Technical school or college 10 (33) 13 (45)
Graduate school 14 (47) 10 (35)
Gender, n (%)
Female 19 (63) 24 (86)
Male 11 (37) 5 (17)
Race/ethnicity, n (%)
White/Caucasian 26 (87) 25 (86)
Black/African-American 3 (10) 3 (10)
Asian/Pacific Islander 1 (3) 1 (3)
Relationship, n (%)
Spouse/partner 21 (72)
Adult child 4 (14)
Friend 3 (10)
Sibling 1 (3)
MCI subtype, n (%)
Amnestic 25 (83)
Nonamnestic 5 (17)
Mean rating of interest in PET
amyloid imaging on a
10-point scale (SD)
(patient n 5 28; care
partner n 5 24)
Baseline 9.07 (2.12) 8.46 (2.94)
At time of qualitative interview* 9.18 (1.68) 8.96 (2.79)
Abbreviations: GED, general education diploma; H.S., high school; MCI,
mild cognitive impairment; PET, positron emission tomography; SD, stan-
dard deviation.
*Paired t-tests showed no significant differences in interest between base-
lines and the time of the qualitative interview.
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that the decision belong to the patient (n 5 7) and those
who voiced agreement and solidarity with the patient
(n 5 13). Those who disagreed with a patient’s decision
voiced concerns that scan results would either be upsetting,
or of little value.
3.4.4. Comparison with previous medical decisions
When queried about how this decision compared with
other medical decisions, participants noted both similarities
and differences. Those viewing the decision as similar to
previous medical decisions made statements indicating the
decision didn’t “feel any different.” Others interpreted the
question as a query regarding the patient’s decisional capac-
ity, “Uh no [this decision is not different], up until now he’s
been able to make his own decisions quite fine.” Explana-
tions of how the decision differed from other medical deci-
sions were provided by care partners more often than
patients and included comments regarding the complexity
of the decision and seriousness of the information to be
gained. Many contrasted this decision, which was posed as
the patient’s elective, with prior medical decisions involving
firm clinical recommendations. For example, “.this is a
choice. This was, for me, a lot more difficult than whether
or not I should have heart surgeries.”
3.4.5. Impact of PTC
While both patients and family members consistently re-
ported PTC to have been helpful and worthwhile, none indi-
cated that the information presented had lessened their
interest in the scan. When directly asked about this, several
participants stated that the PTC content had either no impact
on the outcome of their decision or served to reinforce a de-
cision that had already been made.
Despite statements that PTC did not influence decision
outcomes, analysis of the transcripts revealed that nearly
all participants were actively considering how they would
respond both emotionally and behaviorally to scan results,
an exercise that was introduced and encouraged during
counseling sessions. The following statement typifies such
anticipation, “I think we’re both interested to know where
that [amyloid status] stands.so we can plan for the future.”
Several individuals offered specific examples about the
Table 3
Features of amyloid PET decision-making
Prominent feature of decision-making Examples of supportive participant quotes
Motivated by desire to understand etiology or
course of MCI
“It sure beats waiting for an autopsy.”
“She’s forgetful, and, uh, she just truly wants a definitive answer.that she has the plaque or she
doesn’t.Not that it actually says she has Alzheimer’s, but she just wants to know.”
Motivated by desire for knowledge for
knowledge’s sake
“We were excited about the opportunity because I would prefer to know than not know..and we realize
that it might not effect-help me at all.”
“To me, not knowing is worse than.. knowing.”
Motivated by desire to plan ahead and/or make
informed decisions
“.Then there’s folks like me who want all the information so that I can better make an informed decision
somewhere along the way.”
“I understand what the test does, what you’re looking for and, uhm, it’s going to help me determine what
I’m going to do with my life in the future.”
“I prefer to make decisions with as much information as I can get and I’ve always been that way.”
“Because like I said before, it’s all about planning.”
Easy process “Okay, well you pose it as an option. I pose it as an opportunity. And so, if it’s an opportunity then um, to
me it’s a no-brainer. No pun intended!”
“I mean it was pretty cut and dried, um.from the beginning that he, if he was chosen for that group he
would want to have the scan, he would want to know the results.”
“Well I really didn’t think about it twice. I figured the more understanding there is, the better.”
Pre-test counseling helpful but did not impact
decision outcome
“It was never any question that we were going to do it.[but] she [the pre-test counselor] did make it much
clearer for me what. what they’re going to do, what the tests are going to look like.”
“I think I always wanted to scan regardless of that [pre-test counseling]. And that the information just
reinforced that.”
“No [counseling didn’t influence the decision], but I listened towhat she [pre-test counselor] had to say and
it was. I mean it was interesting and she had more concrete information about it to share, so it was
worth it. It was worth it.”
“You know, it did give her more information, but it was, it didn’t influence her, her decision to do it or not.”
Decision similar to and different from other
medical decisions
Similarities
“I think it was pretty similar [to other medical tests] because both equate to understanding and knowing a
little more than if I didn’t do it.”
“She’s always been like ‘know what you’re dealing with and then you have more information to deal with
it.’ Not kind of bury her head in the sand regarding anything. At one point she had a lump on her breast
and she went and got the mammogram and the biopsy and she’s not somebody [to say], ‘Don’t tell me
what’s wrong with me.’”
Differences
“Well it is [different] in the sense that it’s optional, but it would be hard for me to opt out, because.we
really want to know.”
Abbreviations: MCI, mild cognitive impairment; PET, positron emission tomography.
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conduct of advance care and estate planning. For some, spec-
ulation about behavioral responses extended beyond prac-
tical planning. One care partner, for example, expressed
significant concern regarding a potentially risky reaction to
a positive scan, “I’m afraid in a way that he will maybe
even try moving out or something.because he keeps saying
that he doesn’t want to be a burden.”
4. Discussion
We report findings from qualitative interviews with 30
MCI care dyads following PTC sessions for amyloid PET
that culminated with the instruction to carefully consider
the counseling discussion before finalizing a decision to
schedule a scan or not. Our analysis showed that, in most
cases, decisions about amyloid imaging were being made
relatively quickly and were characterized by a dispropor-
tionate focus on the potential benefits of learning a patient’s
brain amyloid status, with little consideration of possible
drawbacks or limitations of doing so.
The decision to pursue PET amyloid imaging or not is an
example of what decision scientists refer to as a preference
sensitive decision, meaning that tradeoffs are involved and
those tradeoffs should be weighed in light of an individual
patient’s values and preferences [16]. Although initially
applied to treatment decisions, the concept of preference
sensitive decision-making is equally useful in discussions
regarding diagnostic testing and has been invoked in
analyses of the benefits of mammography and prostate-
specific antigen testing under circumstances where the ben-
efits of screening do not clearly outweigh the risks [17–19].
Commentaries on the tradeoffs associated with disclosing
amyloid imaging results to nondemented individuals focus
on the potential for psychological distress [5], discrimination
[20] and, in research settings, interference with scientific ob-
jectives [21], as risks to be weighed against the personal
benefit that a patient or research participant may derive
from learning their brain amyloid status. The lack of effective
interventions for secondary prevention of dementia also fac-
tors into tradeoff calculations. Our previous study using
mock disclosure of hypothetical amyloid PET results re-
vealed a tendency for persons with MCI to perceive inherent
value in learning one’s brain amyloid status, irrespective of
the result or whether the result would yield a change in the
treatment plan [7]. A recent study of 20 patient-caregiver
dyads, including 5 MCI cases, found that the potential to
clarify one’s diagnosis was reported, in retrospect, to be a
common driver of decisions to pursue amyloid imaging,
whereas perceived lack of direct benefit and impact on clin-
ical care were reasons to decline scanning [22]. The present
study is the first prospective investigation to describe similar
anticipated benefits of testing among patients with MCI and
care partners who are actively considering amyloid imaging.
Our analysis clearly demonstrates that amyloid imaging
candidates and their care partners appreciate the preference
sensitive nature of amyloid imaging decisions but offer no
support for the notion that these individuals are routinely
wrestling with the aforementioned tradeoffs. Rather, amy-
loid imaging candidates place a high value on gaining
knowledge and understanding and that value is reported to
be driving decisions in favor of learning one’s brain amyloid
status, with minimal regard for potential drawbacks to the
testing. The latter finding is concerning in light of recent
studies showing that 40%–50% of cognitively intact partic-
ipants may experience dissatisfaction on realizing the limita-
tions of what can be learned from an amyloid scan following
results disclosure [23,24]. In a study of symptomatic
individuals, nearly one-third (8 out of 26) reported feeling
upset, hopeless, or depressed in the months following a diag-
nostic evaluation that included amyloid PET results disclo-
sure, even though many others in the sample felt relieved
[22]. The extent to which pretest expectations may impact
reactions to amyloid PET results disclosure is unknown.
In contrast to the strong pretest interest in amyloid imag-
ing observed in our study and hypothetical interest reported
in surveys of cognitively healthy adults [25,26], a recent
investigation of 63 cognitively healthy participants found
that only 17% were interested in learning the results of
their research amyloid PET scans when actually given the
option [27]. This discrepancy may in part reflect differences
in the perceived personal benefit of learning one’s amyloid
status in individuals who are symptomatic versus those who
are not. For example, a survey of 87 dementia patients and
236 caregivers revealed nearly unanimous interest in amyloid
PETwith the vast majority perceiving clear personal benefits
to learning one’s amyloid status [28]. A similar pattern of
both high interest and perceived benefit was observed in a
recent qualitative study of 38 amnestic MCI research partic-
ipants [9]. The MCI population is unique in that individuals
are experiencing symptoms of cognitive decline but have
not received a clinical dementia diagnosis. Prior research
has shown that many patients with MCI are actively striving
to understand the implications of their symptoms for cogni-
tive health in the foreseeable future [29,30]. In a previous
study, more than half of a sample of 60 MCI patients, and
35% of their family care partners, endorsed the view that
MCI is “puzzling,” and 40% of patients and 20% care
partners viewedMCI as “amystery” [30]. These data provide
context for the current findings of high interest in amyloid im-
aging despite the lack of a secondary prevention strategy for
dementia to be implemented based on scan results.
Our finding that a small minority of individuals may equate
amyloid PET positivity with AD is consistent with Grill et al.
[22] study of reactions to amyloid PET results disclosure in a
clinically heterogeneous population in which the most
commonly cited reasons for undergoing amyloid imaging
were to receive a definitive diagnosis and to learn if one had
AD. Both studies observed this phenomenon in care partners
as well as patients, suggesting that adopting a view of amyloid
PETas a definitive test for AD is not an oversimplification that
can only be ascribed to cognitive impairment within patients.
Furthermore, the emergence of this phenomenon in the
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present study, in which participants were interviewed before
the scan was conducted, suggests similar caution in assuming
a miscommunication during the results disclosure process.
Although amyloid positivity in the context of MCI aligns
with the 2018 National Institute on Aging and Alzheimer’s
Association classification of Alzheimer’s pathologic change
with MCI [31] and the 2011 National Institute on Aging and
Alzheimer’s Association classification of MCI due to AD
[32], our team did not expect participants to describe amyloid
scans as providing definitive information about whether one
with MCI presently has AD. Our PTC protocol explicitly re-
frains from characterizing amyloid PET as a test for AD.
Rather, our counselors use meta-analytically derived esti-
mates to provide the risk of developing AD dementia symp-
toms within a 2-year period based on whether a person with
MCI has elevated amyloid levels or not [7]. Pretest counselors
also emphasize that amyloid scans measure only one of the
two pathologies required for a definitive AD diagnosis.
Although only 6 of our 30 (20%) participants characterized
amyloid PETas a definitive test for AD, these findings warrant
further investigation and underscore the need, in the mean-
time, to clearly and unequivocally emphasize the limitations
of amyloid PET when counseling cognitively impaired pa-
tients and their families before testing.
Our results should be interpreted in light of several limi-
tations. First, our ability to characterize decisions about am-
yloid PET was constrained by the fact that individuals who
agreed to our parent study were highly motivated to undergo
amyloid PET, limiting our ability to balance our sample with
an adequate number of scan decliners. Second, we focused
on factors influencing the decision to learn one’s brain amy-
loid status in a research setting. Participants were relatively
highly educated, had formally demonstrated capacity to con-
sent to amyloid imaging, undergone PTC, and were well
supported by their care partners. Findings from this highly
self-selected sample may not generalize to the broader
pool of candidates for amyloid imaging. While research set-
tings currently represent the most likely context for an indi-
vidual to undergo amyloid PET, other factors may influence
decisions about amyloid imaging in clinical practice. Such
factors may include financial costs or concerns regarding in-
clusion of test results in the medical record. Clinic patients
are also likely to have more medical comorbidities than
ADRC participants, which may factor in unknown ways
into decisions about amyloid PET. Our sample also lacked
racial/ethnic diversity. The extent to which motivations to
pursue amyloid imaging may be culturally driven is un-
known. Finally, our sample was small and should not be
used as a basis for estimating the frequency with which
various motivations for pursuing amyloid PET occur.
In summary, this qualitative analysis of motivations for pur-
suing amyloid PET inMCI revealed two influential factors: (1)
the potential to gain a better understanding ofMCI etiology and
prognosis, and thereby plan ahead, and (2) the potential to learn
one’s brain amyloid status for knowledge’s sake, regardless of
whether the information is actionable. Instances of potentially
overstating the value of amyloid imaging by characterizing
the scan as an AD test were noted while mention of drawbacks
were minimal, even among care partners. These findings sug-
gest that having a care partner present may be insufficient to
safeguard against the temptation to equate amyloid PET posi-
tivity with a definitive AD diagnosis. PTC discussions should
not only include the limitations of amyloid PET in MCI but
also highlight the same. Additional research should include
more representative samples and examinewhether minimizing
the risks of amyloid imaging before scanning has adverse
consequences following results disclosure.
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RESEARCH IN CONTEXT
1. Systematic review: Combinations of the keywords
“amyloid imaging,” “mild cognitive impairment,”
and “ethics” were searched in PubMed through
January 1, 2018. This search yielded four reports of
psychological reactions to disclosure of amyloid imag-
ing results, two in cognitively healthy, and two cogni-
tively impaired older adults, including a retrospective
qualitative analysis of factors influencing the decision
to pursue amyloid positron emission tomography. The
search also revealed two reports of comprehension of
amyloid imaging results, one in cognitively healthy in-
dividuals, andone inmild cognitive impairment.These
studies provide evidence of both positive and negative
reactions to receiving amyloid positron emission to-
mography results.
2. Interpretation: The present study adds to this body of
research by characterizing the decision-making pro-
cess mild cognitive impairment patients and their
familymemberswhile actively contemplating amyloid.
3. Future directions: Our findings of a disproportionate
emphasis on potential benefits among amyloid posi-
tron emission tomography candidates with mild
cognitive impairment should be confirmed in a
larger, more representative sample.
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